News
|
June 11, 2024
UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome
UMass Chan Medical School has received $2.2 million from a nonprofit patient-advocacy organization to contract with Andelyn Biosciences to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome.
News & Press Releases
May 12, 2025
Andelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after DiagnosisAndelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after DiagnosisPress Release
May 6, 2025
Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.Press Release
February 18, 2025
Andelyn Biosciences Expands AAV Curator® Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and HarvardAndelyn Biosciences Expands AAV Curator® Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and HarvardPress Release
View All News & Press Releases